Desmoda: The latest US FDA-approved oral desmopressin solution for all age groups

ABSTRACT

Central diabetes insipidus (CDI) is an uncommon condition characterized by deficient vasopressin secretion, resulting in polyuria, polydipsia, and the potential for dehydration and electrolyte disturbances. Desmopressin, a synthetic form of vasopressin, remains the cornerstone of treatment. Desmoda, an oral liquid formulation of desmopressin approved by the United States Food and Drug Administration, provides a novel, ready-to-use option appropriate for all age demographics, especially infants and individuals with dysphagia. It facilitates accurate, weight-based dosing without requiring tablet handling or refrigeration. Desmoda signifies significant progress in CDI care; however, caution is warranted regarding hyponatremia and its use in patients with renal impairment.